Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, including 32 anti-muscle-specific tyrosine kinase (MuSK)-positive (49%) and 33 anti-MuSK-negative (seronegative) (51%) patients, with 161 anti-AChR-positive MG patients. The anti-MuSK-positive group had a higher frequency of bulbar involvement and respiratory crises. The seronegative group was in between the anti-MuSK positive and the anti-AChR positive groups, being closer to the latter, with regard to the severity of the disease. At the end of follow-up, the outcome of the anti-MuSK-positive patients was not different from that of the anti-AChR-positive patients, although their maintenance corticosteroid dose was higher. The seronegative patients had better outcome than the other two groups.

Original publication

DOI

10.1212/01.wnl.0000254620.45529.97

Type

Journal article

Journal

Neurology

Publication Date

20/02/2007

Volume

68

Pages

609 - 611

Keywords

Adrenal Cortex Hormones, Adult, Autoantibodies, Biomarkers, Brain Stem, Causality, Disease Progression, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Myasthenia Gravis, Neuromuscular Junction, Predictive Value of Tests, Prevalence, Receptor Protein-Tyrosine Kinases, Receptors, Cholinergic, Respiratory Insufficiency, Serologic Tests, Treatment Outcome